Last week, InvestorPlace’s Joel Baglole claimed that  $Novav...

Last week, InvestorPlace’s Joel Baglole claimed that $Novavax (NVAX.US)$ had fallen out of the vaccine race. That’s looking more prescient now that the public has learned just how much the company is struggling.

This development is disappointing but shouldn’t be unexpected. Novavax has experienced other supply-chain issues that have hindered its large-scale supply deals. For instance, it has had to delay ramping up its per-month production of doses due to a variety of supply constraints.With other companies outpacing Novavax, there are better opportunities to be bullish in the vaccine stocks space. $Ginkgo Bioworks (DNA.US)$ $Vaxart (VXRT.US)$